市場調查報告書

重症肌無力(MG) - 市場洞察,流行病學,市場預測(2027年)

Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 703502
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
重症肌無力(MG) - 市場洞察,流行病學,市場預測(2027年) Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的重症肌無力(MG)的2016年的總患病數12萬9,267人,市場規模估計為29億9,810萬美元。

本報告提供主要7個國家的重症肌無力(MG)市場調查,疾病概要,患者背景,主要7個國家重症肌無力的患病數、診斷數的預測(今後10年份),診斷指南,上市藥及新藥概要,市場成長要素與阻礙,競爭情形等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 重症肌無力市場概要

第3章 市場佔有率(最新值)

第4章 市場佔有率(預測值)

第5章 疾病概要:重症肌無力(MG)

  • 簡介
  • 重症肌無力的種類
  • 重症肌無力的分類
  • 病因
  • 遺傳的概要
  • 危險因素
  • 徵兆與症狀
  • 病理生理學
  • 合併症
  • 診斷

第6章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數
  • 主要7個國家的總患病數
  • 重症肌無力的流行病學:各國
    • 美國
      • 前提和根據
      • 重症肌無力的總患病數
      • 重症肌無力的總患病數:性別
      • 重症肌無力的診斷數
      • 重症肌無力的診斷數:各重症度
      • 重症肌無力的診斷數:各自身抗體
    • 德國
      • 重症肌無力的總患病數
      • 重症肌無力的總患病數:性別
      • 重症肌無力的診斷數
      • 重症肌無力的診斷數:各重症度
      • 重症肌無力的診斷數:各自身抗體
    • 法國
      • 重症肌無力的總患病數
      • 重症肌無力的總患病數:性別
      • 重症肌無力的診斷數
      • 重症肌無力的診斷數:各重症度
      • 重症肌無力的診斷數:各自身抗體
    • 義大利
      • 重症肌無力的總患病數
      • 重症肌無力的總患病數:性別
      • 重症肌無力的診斷數
      • 重症肌無力的診斷數:各重症度
      • 重症肌無力的診斷數:各自身抗體
    • 西班牙
      • 重症肌無力的總患病數
      • 重症肌無力的總患病數:性別
      • 重症肌無力的診斷數
      • 重症肌無力的診斷數:各重症度
      • 重症肌無力的診斷數:各自身抗體
    • 英國
      • 重症肌無力的總患病數
      • 重症肌無力的總患病數:性別
      • 重症肌無力的診斷數
      • 重症肌無力的診斷數:各重症度
      • 重症肌無力的診斷數:各自身抗體
    • 日本
      • 重症肌無力的總患病數
      • 重症肌無力的總患病數:性別
      • 重症肌無力的診斷數
      • 重症肌無力的診斷數:各重症度
      • 重症肌無力的診斷數:各自身抗體

第7章 目前治療方法

  • 重症肌無力的管理相關國際共識指導
  • 對重症肌無力的日本臨床指南

第8章 未滿足需求

第9章 上市藥

  • Key Cross Competition
  • Soliris:Alexion Pharmaceuticals
    • 醫藥品概要
    • 法規的里程碑
    • 優點和缺點
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Mestinon:Valeant Pharmaceuticals
  • Prograf:Astellas Pharma Inc.
  • venoguroburinIH:田邊三菱製藥

第10章 新藥

  • Key Cross Competition
  • 第三階段試驗
  • Firdapse:Catalyst Pharmaceuticals
    • 醫藥品概要
    • 開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Hizentra:CSL Behring
  • IGIV-C:Grifols Therapeutics
  • 第二階段實驗
  • Rozanolixizumab: UCB Pharma
  • CFZ533: Novartis
  • Efgartigimod : Argenx
  • RA101495: Ra Pharmaceuticals

第11章 市場分析重症肌無力:主要7個國家

  • 主要的觀察
  • 主要7個國家重症肌無力的市場規模

第12章 市場展望:各國

  • 美國:市場預測
    • 市場規模
    • 重症肌無力的市場規模
    • 市場規模:各上市藥
    • 市場規模:各新藥
  • 歐盟5國:市場預測
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本:市場預測

第13章 市場成長要素

第14章 市場障礙

第15章 附錄

第16章 報告方法

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0140

DelveInsight's "Myasthenia Gravis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Myasthenia Gravis market report provides current treatment practices, emerging drugs, Myasthenia Gravis market share of the individual therapies, current and forecasted Myasthenia Gravis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Myasthenia Gravis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Myasthenia Gravis Disease Understanding and Treatment Algorithm

The DelveInsight Myasthenia Gravis market report gives a thorough understanding of the Myasthenia Gravis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Myasthenia Gravis.

Treatment

It covers the details of conventional and current medical therapies available in the Myasthenia Gravis market for the treatment of the condition. It also provides Myasthenia Gravis treatment algorithms and guidelines in the United States, Europe, and Japan.

Myasthenia Gravis Epidemiology

The Myasthenia Gravis epidemiology division provide insights about historical and current Myasthenia Gravis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Myasthenia Gravis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Myasthenia Gravis Epidemiology

The epidemiology segment also provides the Myasthenia Gravis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Myasthenia Gravis Drug Chapters

Drug chapter segment of the Myasthenia Gravis report encloses the detailed analysis of Myasthenia Gravis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Myasthenia Gravis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Myasthenia Gravis treatment.

Myasthenia Gravis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Myasthenia Gravis treatment.

Myasthenia Gravis Market Outlook

The Myasthenia Gravis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Myasthenia Gravis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Myasthenia Gravis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Myasthenia Gravis market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Myasthenia Gravis market in 7MM.

The United States Market Outlook

This section provides the total Myasthenia Gravis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Myasthenia Gravis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Myasthenia Gravis market size and market size by therapies in Japan is also mentioned.

Myasthenia Gravis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Myasthenia Gravis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Myasthenia Gravis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Myasthenia Gravis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Myasthenia Gravis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Myasthenia Gravis emerging therapies.

Reimbursement Scenario in Myasthenia Gravis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Myasthenia Gravis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Myasthenia Gravis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Myasthenia Gravis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Myasthenia Gravis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Myasthenia Gravis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Myasthenia Gravis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Myasthenia Gravis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Myasthenia Gravis market

Report Highlights

  • In the coming years, Myasthenia Gravis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Myasthenia Gravis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Myasthenia Gravis. Launch of emerging therapies will significantly impact the Myasthenia Gravis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Myasthenia Gravis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Myasthenia Gravis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Myasthenia Gravis Pipeline Analysis
  • Myasthenia Gravis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Myasthenia Gravis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Myasthenia Gravis Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Myasthenia Gravis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Myasthenia Gravis market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Myasthenia Gravis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Myasthenia Gravis market size during the forecast period (2017-2030)?
  • At what CAGR, the Myasthenia Gravis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Myasthenia Gravis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Myasthenia Gravis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Myasthenia Gravis?
  • What is the historical Myasthenia Gravis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Myasthenia Gravis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Myasthenia Gravis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Myasthenia Gravis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Myasthenia Gravis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Myasthenia Gravis in the USA, Europe, and Japan?
  • What are the Myasthenia Gravis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Myasthenia Gravis?
  • How many therapies are developed by each company for Myasthenia Gravis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Myasthenia Gravis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Myasthenia Gravis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myasthenia Gravis and their status?
  • What are the key designations that have been granted for the emerging therapies for Myasthenia Gravis?
  • What are the global historical and forecasted market of Myasthenia Gravis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis market
  • To understand the future market competition in the Myasthenia Gravis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Myasthenia Gravis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Myasthenia Gravis market
  • To understand the future market competition in the Myasthenia Gravis market

Table of Contents

1. Key Insights

2. Executive Summary of Myasthenia Gravis

3. Competitive Intelligence Analysis for Myasthenia Gravis

4. Myasthenia Gravis: Market Overview at a Glance

  • 4.1. Myasthenia Gravis Total Market Share (%) Distribution in 2017
  • 4.2. Myasthenia Gravis Total Market Share (%) Distribution in 2030

5. Myasthenia Gravis: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Myasthenia Gravis Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Myasthenia Gravis Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Myasthenia Gravis Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Myasthenia Gravis Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Myasthenia Gravis Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Myasthenia Gravis Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Myasthenia Gravis Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Myasthenia Gravis Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Myasthenia Gravis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Myasthenia Gravis Treatment and Management
  • 8.2. Myasthenia Gravis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Myasthenia Gravis Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Myasthenia Gravis: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Myasthenia Gravis Market Size in 7MM
  • 13.3. Myasthenia Gravis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Myasthenia Gravis Total Market Size in the United States
    • 15.1.2. Myasthenia Gravis Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Myasthenia Gravis Total Market Size in Germany
    • 15.3.2. Myasthenia Gravis Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Myasthenia Gravis Total Market Size in France
    • 15.4.2. Myasthenia Gravis Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Myasthenia Gravis Total Market Size in Italy
    • 15.5.2. Myasthenia Gravis Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Myasthenia Gravis Total Market Size in Spain
    • 15.6.2. Myasthenia Gravis Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Myasthenia Gravis Total Market Size in the United Kingdom
    • 15.7.2. Myasthenia Gravis Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Myasthenia Gravis Total Market Size in Japan
    • 15.8.3. Myasthenia Gravis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Myasthenia Gravis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Myasthenia Gravis Epidemiology (2017-2030)
  • Table 2 : 7MM Myasthenia Gravis Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Myasthenia Gravis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Myasthenia Gravis Epidemiology in Germany (2017-2030)
  • Table 6 : Myasthenia Gravis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Myasthenia Gravis Epidemiology in France (2017-2030)
  • Table 8 : Myasthenia Gravis Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Myasthenia Gravis Epidemiology in Italy (2017-2030)
  • Table 10 : Myasthenia Gravis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Myasthenia Gravis Epidemiology in Spain (2017-2030)
  • Table 12 : Myasthenia Gravis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Myasthenia Gravis Epidemiology in the UK (2017-2030)
  • Table 14 : Myasthenia Gravis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Myasthenia Gravis Epidemiology in Japan (2017-2030)
  • Table 16 : Myasthenia Gravis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Myasthenia Gravis Epidemiology (2017-2030)
  • Figure 2 : 7MM Myasthenia Gravis Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Myasthenia Gravis Epidemiology in the United States (2017-2030)
  • Figure 4 : Myasthenia Gravis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Myasthenia Gravis Epidemiology in Germany (2017-2030)
  • Figure 6 : Myasthenia Gravis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Myasthenia Gravis Epidemiology in France (2017-2030)
  • Figure 8 : Myasthenia Gravis Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Myasthenia Gravis Epidemiology in Italy (2017-2030)
  • Figure 10 : Myasthenia Gravis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Myasthenia Gravis Epidemiology in Spain (2017-2030)
  • Figure 12 : Myasthenia Gravis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Myasthenia Gravis Epidemiology in the UK (2017-2030)
  • Figure 14 : Myasthenia Gravis Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Myasthenia Gravis Epidemiology in Japan (2017-2030)
  • Figure 16 : Myasthenia Gravis Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)